Collectionner le produit
Détails du produit
Source
Chimeric Monoclonal Anti-TNF-alpha Antibody, Human IgG1 (13B8) is recombinantly expressed in HEK293. It consists of mouse variable regions genetically fused to human IgG1 constant domains.
Antibody Type
Recombinant Monoclonal
Clone
13B8
Isotype
Human IgG1, Kappa
Host Species
Mouse
Reactivity
Human
Immunogen
Recombinant Human TNF-alpha derived from human HEK293 cells
Specificity
This product is a specific antibody that has a specific response to tnf-α in humans, Canine and Rhesus macaque.
Purification
Protein A purified.
Aggregation
Less than 5%, as determined by SEC-MALS.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-ELISA
ImmobilizedHuman TNF-alpha Protein, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) at 2μg/mL (100μL/well) can bind Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) with a linear range of 0.05-1.56 ng/mL (QC tested).
Protocol
Bioactivity-SPR
Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNF-alpha, His Tag (Cat. No. TNA-H5228) with an affinity constant of 0.133 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Protocol
Bioactivity-BLI
Loaded Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) on Protein A Biosensor, can bind Human TNF-alpha, His Tag (active trimer) (MALS verified) (Cat. No. TNA-H5228) with an affinity constant of 1.03 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) on Protein A Biosensor, can bind Human TNF-alpha, premium grade (MALS verified) (Cat. No. TNA-H4211) with an affinity constant of 2.97 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Monoclonal Anti-TNF-alpha antibody, Human IgG1 (13B8) (Cat. No. TNA-AM493) on Protein A Biosensor, can bind Canine TNF-alpha, His Tag (Cat. No. TNA-C52H3) with an affinity constant of 2.24 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Tumor necrosis factor α
- Catégorie：
- Nombre de médicaments répertoriés：
68 Détails
- Nombre de médicaments cliniques：
74 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
